PRESS RELEASE published on 11/14/2024 at 07:00, 1 year 7 months ago CEWE: With an increase in earnings after nine months, 2024 targets has been confirmed CEWE Stiftung & Co. KGaA confirms 2024 targets with increased earnings after nine months. Group turnover up by 6.3% to 481.6 million euros, Group EBIT rises to 5.5 million euros EBIT 2024 Targets Earnings Turnover CEWE
BRIEF published on 10/11/2024 at 14:05, 1 year 8 months ago CEWE CFO Olaf Holzkämper to Resign in 2025 for Health Reasons CFO Resignation CEWE Group Health Reasons Olaf Holzkämper Board Transition
BRIEF published on 10/11/2024 at 14:05, 1 year 8 months ago Le directeur financier de CEWE, Olaf Holzkämper, démissionnera en 2025 pour des raisons de santé Raisons De Santé Démission Du Directeur Financier Olaf Holzkämper Groupe CEWE Transition Du Conseil D'administration
PRESS RELEASE published on 10/11/2024 at 14:00, 1 year 8 months ago CEWE Group announces resignation of Chief Financial Officer Olaf Holzkämper in the course of 2025 CEWE Group announces resignation of Chief Financial Officer Olaf Holzkämper in 2025 due to health reasons after almost 20 years with the company Chief Financial Officer Resignation CEWE Group Health Reasons Olaf Holzkämper
PRESS RELEASE published on 08/29/2024 at 09:16, 1 year 9 months ago Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen Starke Entwicklung bei CEWE Stiftung & Co. KGaA im zweiten Quartal 2024; Umsatz- und Ergebniswachstum; hohe Marktposition als Premium-Anbieter CEWE Stiftung & Co. KGaA Fotofinishing Halbjahreszahlen 2024 Premium-Anbieter Kursziel 148 Euro
PRESS RELEASE published on 08/16/2024 at 10:46, 1 year 10 months ago Original-Research: CEWE Stiftung & Co. KGaA (von Montega AG): Kaufen CEWE Stiftung & Co. KGaA veröffentlicht positive Halbjahreszahlen und bestätigt Prognose für 2024. Analysten von Montega AG empfehlen Kauf mit Kursziel 148,00 EUR Montega AG Kaufempfehlung Prognose 2024 CEWE Stiftung Halbjahreszahlen
BRIEF published on 08/15/2024 at 14:43, 1 year 10 months ago CEWE Stiftung & Co. KGaA Decides to Buy Back Own Company Shares Share Buyback Treasury Shares SDAX CEWE Board Decision
BRIEF published on 08/15/2024 at 14:43, 1 year 10 months ago CEWE Stiftung & Co. KGaA décide de racheter ses propres actions Actions Propres Rachat D'actions SDAX CEWE Décision Du Conseil
PRESS RELEASE published on 08/15/2024 at 14:38, 1 year 10 months ago EQS-Adhoc: CEWE Stiftung & Co. KGaA: CEWE decides to buy back own company shares CEWE Stiftung & Co. KGaA announces a share buyback program to repurchase up to 250,000 own shares, representing around 3.3% of share capital, with a volume of up to 20 million euros Share Buyback Treasury Shares Stock Exchange Own Shares CEWE Stiftung
BRIEF published on 08/15/2024 at 07:05, 1 year 10 months ago CEWE Continues Strong Performance: Q2 Turnover and Earnings Growth Photofinishing Turnover Growth CEWE Q2 Earnings Online Print
Published on 06/26/2026 at 14:05, 2 hours 57 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 3 hours 2 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 4 hours 2 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 4 hours 17 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 15:30, 1 hour 32 minutes ago JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 1 hour 39 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 1 hour 39 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 1 hour 40 minutes ago Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 06/26/2026 at 07:00, 10 hours 2 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 10 hours 2 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
